{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T23:16:45Z","timestamp":1740179805830,"version":"3.37.3"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T00:00:00Z","timestamp":1672012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,19]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Extrapulmonary tuberculosis (TB) can occur in patients treated with Janus kinase (JAK) inhibitors. We present a case of rheumatoid arthritis complicated by extrapulmonary TB following baricitinib treatment. A 45-year-old Japanese woman was diagnosed with rheumatoid arthritis at another hospital, and she subsequently started treatment with methotrexate (MTX) at 6.0\u2009mg\/week and prednisolone at 3.0\u2009mg\/day at our institute. The MTX dose was increased to 10\u2009mg\/week, and clinical remission was achieved; however, the disease activity flared up 6\u2009months after the initial visit. Isoniazid (INH) prophylaxis was started following positive T-SPOT\u00ae screening for TB, and baricitinib (Olumiant\u00ae) was introduced 3\u2009weeks later because of an insufficient response to MTX. INH prophylaxis was continued for 6\u2009months. Ten months after starting INH treatment, a painless mass was observed on the left side of the patient\u2019s neck. Magnetic resonance imaging showed enlarged lymph nodes with calcification. A subsequent biopsy and pathologic examination led to a diagnosis of tuberculous lymphadenitis, and the patient was started on anti-TB therapy. Ten months later, the patient was still in remission and doing well. Extrapulmonary TB can be difficult to diagnose because of inconsistent physical and laboratory findings. When treating patients with JAK inhibitors, physicians should be cognisant of the potential for extrapulmonary TB to develop.<\/jats:p>","DOI":"10.1093\/mrcr\/rxac098","type":"journal-article","created":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T15:01:00Z","timestamp":1672066860000},"page":"364-367","source":"Crossref","is-referenced-by-count":2,"title":["A case of extrapulmonary tuberculosis after use of baricitinib"],"prefix":"10.1093","volume":"7","author":[{"given":"Tetsuro","family":"Shimada","sequence":"first","affiliation":[{"name":"Department of Orthopaedic Surgery, Faculty of Medicine, Fukuoka University , Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Maeyama","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Faculty of Medicine, Fukuoka University , Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonobu","family":"Hagio","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Faculty of Medicine, Fukuoka University , Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihide","family":"Muraoka","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Faculty of Medicine, Fukuoka University , Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terufumi","family":"Shibata","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Faculty of Medicine, Fukuoka University , Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaro","family":"Yamasaki","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Faculty of Medicine, Fukuoka University , Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiga","family":"Oda","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Faculty of Medicine, Fukuoka University , Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Hamasaki","sequence":"additional","affiliation":[{"name":"Department of Pathology, Fukuoka University School of Medicine , Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6187-4957","authenticated-orcid":false,"given":"Takuaki","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Faculty of Medicine, Fukuoka University , Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,12,26]]},"reference":[{"key":"2023061920013414400_R1","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s40265-018-0908-4","article-title":"Baricitinib: a review in rheumatoid arthritis","volume":"78","author":"Al-Salama","year":"2018","journal-title":"Drugs"},{"key":"2023061920013414400_R2","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.2174\/0929867325666180327093502","article-title":"An update on JAK inhibitors","volume":"26","author":"Musumeci","year":"2019","journal-title":"Curr Med Chem"},{"key":"2023061920013414400_R3","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.mayocp.2020.01.039","article-title":"Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: a systematic review and meta-analysis","volume":"95","author":"Wang","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"2023061920013414400_R4","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/jcpt.13142","article-title":"Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis","volume":"45","author":"Ho Lee","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"2023061920013414400_R5","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/acr.24007","article-title":"Efficacy and safety of long-term baricitinib with and without methotrexate for the treatment of rheumatoid arthritis: experience with baricitinib monotherapy continuation or after switching from methotrexate monotherapy or baricitinib plus methotrexate","volume":"72","author":"Fleishchmann","year":"2020","journal-title":"Arthritis Care Res"},{"key":"2023061920013414400_R6","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","article-title":"Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study","volume":"76","author":"Dougados","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023061920013414400_R7","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1148\/rg.2019190109","article-title":"Extrapulmonary tuberculosis: pathophysiology and imaging findings","volume":"39","author":"Rodriguez-Takeuchi","year":"2019","journal-title":"Radiographics"},{"key":"2023061920013414400_R8","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3889\/oamjms.2019.215","article-title":"Comparison of the microwave-heated Ziehl-Neelsen stain and conventional Ziehl-Neelsen method in the detection of acid-fast bacilli in lymph node biopsies","volume":"7","author":"Ahmed","year":"2019","journal-title":"Open Access Maced J Med Sci"},{"key":"2023061920013414400_R9","article-title":"Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme","volume":"6","author":"Ohen","year":"2020","journal-title":"RMD Open"},{"key":"2023061920013414400_R10","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","article-title":"Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2023061920013414400_R11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3899\/jrheum.171361","article-title":"Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment","volume":"46","author":"Smolen","year":"2019","journal-title":"J Rheumatol"},{"key":"2023061920013414400_R12","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1136\/annrheumdis-2019-216852","article-title":"Infections in baricitinib clinical trials for patients with active rheumatoid arthritis","volume":"79","author":"Winthrop","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023061920013414400_R13","first-page":"585","article-title":"Tuberculous lymphadenitis","volume":"57","author":"Mohapatra","year":"2009","journal-title":"J Assoc Physicians India"},{"key":"2023061920013414400_R14","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"2023061920013414400_R15","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1080\/14397595.2020.1794103","article-title":"Efficacy and safety of peficitinib in rheumatoid arthritis","volume":"30","author":"Kaneko","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2023061920013414400_R16","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2023061920013414400_R17","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"2023061920013414400_R18","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1164\/rccm.201909-1874ST","article-title":"Treatment of drug-resistant tuberculosis. An official ATS\/CDC\/ERS\/IDSA clinical practice guideline","volume":"200","author":"Nahid","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2023061920013414400_R19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ijid.2014.12.007","article-title":"Imaging in tuberculosis","volume":"32","author":"Skoura","year":"2015","journal-title":"Int J Infect Dis"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxac098\/48486714\/rxac098.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/7\/2\/364\/50646450\/rxac098.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/7\/2\/364\/50646450\/rxac098.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T20:06:35Z","timestamp":1687205195000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/7\/2\/364\/6960963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,26]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,12,26]]},"published-print":{"date-parts":[[2023,6,19]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxac098","relation":{},"ISSN":["2472-5625"],"issn-type":[{"type":"electronic","value":"2472-5625"}],"subject":[],"published-other":{"date-parts":[[2023,7,1]]},"published":{"date-parts":[[2022,12,26]]}}}